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Malignant brain tumor is one of the most lethal forms of cancers.  In the United 
States alone, approximately 20,500 new cases of primary malignant brain and central 
nervous system tumors are expected to be diagnosed in 2007 with 12,740 deaths 
estimated. Treatment of malignant brain tumor remains a major challenge despite recent 
advances in surgery and other adjuvant therapies, such as chemotherapy. The failure of 
potential effective chemotherapeutics for brain tumor treatment is usually not due to the 
lack of potency of the drug, but rather can be attributed to lack of therapeutic strategies 
capable of overcoming blood brain barrier for effective delivery of drug to the brain 
tumor.   
In this thesis, we developed a minimally invasive sustained release system for 
glioma therapy.  The present study was initiated in an effort to incorporate Doxorubicin 
(DOX) loaded PLGA particle into an agarose gel, which can provide a continuous release 
of DOX locally to the tumor site.  DOX, a toposiomearase II inhibitor, is not currently 
used clinically for brain tumor treatment because when delivered systemically it does not 
cross BBB.  Our hydrogel particle system can overcome this shortcoming of DOX.  The 
results from this study demonstrate that the DOX/PLGA particle gel system can maintain 
the bioactivity of DOX and sustained release DOX for at least 15 day in vitro. The result 
of in vivo study showed the DOX/PLGA particle gel treated group had significantly 
extended the medium survival of 9L glioma bearing rat from 21 days to 29 days. 
Therefore, the success experience of this local and sustained delivery device might 





1.1 STATEMENT OF PROBLEM 
Malignant brain tumor is one of the most lethal forms of cancers.  Although the 
incidence rate of primary malignant brain tumor is low (7.4 cases per 100,000 person-
years) (CBTRUS 2006), death rate is still very high.  In the United States alone, 
approximately 20,500 new cases of primary malignant brain and central nervous system 
tumors are expected to be diagnosed in 2007 with 12,740 deaths estimated. (Jemal et al. 
2007)   The need for treating this devastating disease has intensified the research in drug 
discovery and drug delivery to brain tumor. However, prognosis for patients with 
malignant brain tumor remains poor. 
The traditional treatment of malignant brain tumor is surgical resection, followed 
by radiation therapy or chemotherapy; however, they are only capable of prolonging 
survival rather than eradicating the disease. With high-grade gliomas such as 
glioblastoma multiforme (GBM), the median survival time after surgical resection is six 
months and the addition of radiation therapy extends survival to nine months due to the 
recurrence of the tumor (Barker et al 1998).  Currently, chemotherapy is not the primary 
treatment of choice for malignant brain tumor because most therapeutic agents for brain 
tumor cannot reach therapeutic doses within the brain due to the blood brain barrier 
(BBB).  Only small (< 500 Dalton), lipid soluble molecules can passively cross the 
barrier (Lesniak and Brem 2004).  To achieve the therapeutic level of drug in brain 
tumor, the drug is administered systemically, which leads to serious side effects.  One 
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possible way to overcome the BBB is to administer the drug directly at the site of brain 
tumor. However, the risk of infections will increase with administration frequency.  
Thus, it will be beneficial to brain tumor treatment to develop a minimally invasive 
sustained drug delivery system that can continuously release therapeutic agents into the 
brain (Pardridge 2003).  
One approach for intracranial drug delivery is to surgically implant a polymer 
system that is capable of sustained release of drug at the tumor site.  Currently, Gliadel® 
Wafer is the only marketed therapy for recurrent tumor of GBM, in conjunction with 
radiation therapy and surgery (Kleinberg et al. 2004).  It continuously releases 
Carmustine (BCNU), a chemotherapeutic agent, in the tumor resection site through the 
degradation of the polymer wafer.  However, the agent is delivered from biodegradable 
wafers, which may or may not completely cover the surface after resection. Most studies 
showed majority of BCNU can only penetrate within 1-5 mm from the implantation site 
(Fleming and Saltzman. 2002), thus not reaching all of the tumor cells. Similar problems 
were also observed in other delivery systems (rods, sheets, and microparticles).  
Therefore, there is a great need to improve the current drug delivery system.  
 
1.2 HYPOTHESIS 
For successful treatment of brain tumor with an intracranial implant, the 
therapeutic agents must be released over several weeks from the delivery system and 
penetrate through the tissue surrounding the implant to reach cancer cells.  Thus, a 
conformal coating implant will enhance the efficiency of the drug delivery by 
maximizing the contact area between implant and cancer cells.  Our central hypothesis 
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is: local and sustained release of chemotherapeutic agent will increase the efficacy of 
chemotherapy in the treatment of gliomas while minimizing the systemic side effects.  
For sustained delivery, biodegradable polymeric particles poly(lactic-co-glycolic acid) 
were used for the slow release of therapeutic agent doxorubicin (DOX). For local 
delivery, hydrogel was used as a scaffold for the particles and allowed DOX to diffuse 
to the brain tumor cells. 
 
1.3 OBJECTIVES 
The overall goal of this thesis research is to develop a minimally invasive hydrogel-
particle composite system capable of local and sustained delivery of DOX to treat 
glioma. NTo test our hypothesis and accomplish our goal, the following objectives were 
set: 
1. Develop the DOX encapsulated hydrogel-particle composite and characterize its in 
vitro performance. 
2. Evaluate the performance of the DOX encapsulated hydrogel-particle composite in a 
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Treatment of malignant brain tumor remains a major challenge despite recent 
advances in surgery and other adjuvant therapy.  Chemotherapy of brain tumor has been 
particularly inefficient, due to the special barriers in the central nervous system (CNS).  
The failure of potential effective chemotherapeutics for brain tumor treatment is usually 
not due to the lack of potency of the drug, but rather can be attributed to lack of 
therapeutic strategies capable of overcoming CNS barriers for effective delivery of drug 
to the brain tumor.  Thus, in this chapter, we will first review the barriers in brain tumor 
therapy, and then discuss current strategies to overcome the barriers.   Particularly, we 
will focus more on applying the local implant strategy to enhance the effectiveness of 
drug delivery in brain tumor therapy.  
 
2.1 BARRIERS FOR DRUG DELIVERY TO BRAIN TUMOR 
The failure of systemically delivered therapeutic agents to effectively treat brain 
tumor is mainly due to the presence of the highly impermeable blood brain barrier 
(BBB) (Pardridge 2003).  The BBB, which composed of cerebral capillary endothelial 
cells with tight junctions, prevents the passive uptake of hydrophilic and large molecules 
into the brain parenchyma (Goldstein & Bezt. 1986). Only small molecular weight, 
uncharged, and lipophilic molecules can passively cross the barrier, and not all of them 
have therapeutic effect for treating malignant brain tumor (Habgood et al 2000). 
Moreover, the endothelial cells of brain capillaries have fewer pinocytotic vesicles than 
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those of capillaries elsewhere in the body (Pardridge, 2000). The transport of molecules, 
which depends on the cellular transcytosis, is therefore severely compromised.  Finally, 
a number of transport proteins located in the luminal membranes of cerebro capillary 
endothelium are known to be involved in the influx and efflux of endogenous and 
exogenous molecules across the BBB (Kusuhara & Sugiyama, 2001a).   Efflux transport 
proteins such as P-glycoprotein and multidrug resistance associated protein actively 
remove a wide range of chemotherpeutic agents before they cross into the brain 
parenchyma, thus, effectively restrict drugs entering CNS (Kusuhara & Sugiyama, 
2001b; Lee G et al, 2001; Taylor  2002). 
The second barrier for therapeutic drug delivery to the CNS and brain tumor is 
blood-cerebrospinal fluid barrier (BCB).  This barrier is formed by the specialized tight 
junctions of endothelial cells in the choroids plexus.  The BCB closely regulates the 
exchange of molecules between blood and cerebrospinal fluid (CSF), thus it also 
regulates the drug entry into brain parenchyma.  However, the BCB is not as a major 
barrier as the BBB.  The surface area of BCB is approximately 1000 fold less than that 
of the BBB (Pardridge 1997). 
The abnormal microvasculature of brain tumor contributes to the third barrier for 
therapeutic drug delivery to brain tumor, the blood-tumor-barrier (BTB).  The tumor 
microvessles are abnormal; e.g. distended capillary with leaky wall and sluggish flow, 
leading to inconsistent drug delivery.  The leaky tumor vasculature leads to 
accumulation of interstitial fluid, which causes an increase of the interstitial pressure in 
brain tumor and creates a net flow of fluid from the center to the periphery of the tumor 
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and the surrounding tissue.  This further limits the flow and tissue penetration of 
therapeutic agents from the blood stream to the tumor parenchyma (Jain RK 1994). 
These three barriers together compose a very delicate control system to maintain 
homeostasis of the CNS.  However, the same control system that protects the brain from 
foreign substances also restricts the entry of many potential therapeutic agents. There is 
a great need to find an effective drug delivery system that can overcome these barriers. 
This thesis is focused on the drug delivery to overcome the BBB, the major barrier for 
chemotherapeutic agents to reach to the brain tumor. 
 
2.2 CURRENT STRATEGIES TO OVERCOME BLOOD BRAIN BARRER 
Chemotherapy of brain tumor has been particularly inefficient, mainly due to the 
presence of the highly impermeable BBB.  The understanding of BBB has been used in 
the rational design of new therapeutic strategies.   There are a series of techniques that 
have been applied to improve drug delivery efficacy to brain tumor.  These techniques 
can be divided into two main categories: non-invasive methods and invasive methods. 
They are discussed below. 
 
2.2.1 Non-invasive methods 
2.2.1.1 Enhance the lipophilicity of drug 
 As mentioned previously, only small molecular weight, uncharged, and 
lipophilic molecules can passively cross the BBB from systemic circulation (Habgood et 
al 2000).   The first strategy to improve the passive drug-uptake into the brain is to 
increase the lipophilicity of drug by chemical alteration.  Carmustine (BCNU), the 
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active component of Gliadel® wafer, is an alkylating agent used to treat malignant brain 
tumor. Although more than 20 lipophilic carmustine analogs were synthesized, clinical 
trials have not shown improved efficacy of these drugs over carmustine.  (Kornblith & 
Walker. 1988)  The efficacy of alkylating agent is inversely proportional to their 
lipophilicity (Pardrigre 1988). In addition, lipophilic drug tends to bind to plasma 
protein when administrated intravenously, which results in lower drug concentrations 
within the brain and brain tumor (Rautio and Chikhale. 2004).   
  The other method to enhance the lipophilicity of a drug is to encapsulate the 
drug within liposome, a lipid bilayer vesicle.  In particular, the encapsulation of 
doxorubicin (DOX) within liposome has increased the delivery of the drug in 
experimental brain tumor model (Koukourakis MI et al. 2000).  Furthermore, the 
advantage of using liposomal carriers is their ability to incorporate ligands on their 
surface directed to brain capillary receptors.  For example, OX-26, a mouse monoclonal 
antibody (MAb) to the rat transferrin receptor, could attach to the endogenous 
transferrin receptor-mediated transcytosis mechanism to cross the abluminal membrane 
and deliver large molecules into the brain (Friden et al. 1991).  Huwyler and colleagues 
showed that OX-26 conjugated liposome could cross BBB and deliver radioactive 
daunomycin into the brain, while PEGylated liposome (stealth liposome) could not pass 
the BBB (Huwyler 1996).  This delivery system is important for chemotherapeutic drug 
delivery because it permits brain targeting of liposomally encapsulated drugs, and 
consequently reduce the side effects of systemic delivery. 
 
2.2.1.2   Temporary disruption of BBB 
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Instead of modification of chemotherapeutic agents, temporary BBB disruption could be 
considered as a therapeutic strategy in conjunction with systemic administration of 
chemotherapeutic drug for brain tumor treatment.  An ideal BBB disruption method 
should be temporary and reversible so that BBB does not permanently loose its 
protection function for the brain. The first approach to transient BBB disruption is to 
inject hypertonic agents, such as mannitol.  Mannitol shrinks the endothelial cells by 
drawing fluid out of them, and opens the tight junctions for a few hours to allow 
therapeutic drugs entering to brain tumor.  However, administration of mannitol has 
disadvantage of being limited to the vascular supply and exposing a large area of non-
neoplastic brain to chemotherapeutic agents, which could possibly result in severe 
neurotoxic side effect (Millay et al. 1986).  Other compounds, such as RMP-7, can 
increase the tight junction permeability by activating B2 receptor of the endothelial cell, 
thus enhancing the delivery of therapeutic drugs by directly opening of the BBB 
(Emerich et al. 2000).  Although RMP-7 has better specificity to brain tumor capillary 
than normal brain capillary, similar neurotoxic side effect was observed as well 
(Inamura et al. 1994). 
 
2.2.2 Invasive methods 
2.2.2.1 Catheter with pump system  
The simplest and most direct strategy to overcome the barriers to brain tumor is 
to administer therapeutic drug into the tumor via catheter systems.  Currently, several 
implantable catheter pump systems are available for brain tumor therapy. For example, 
the Ommaya reservoir can intermittent bolus injections of therapeutic agents (including 
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DOX, BCNU, cisplatin, interleukin 2 and interferon-γ) to brain tumors (Lesniak and 
Brem 2004).  Recently, more advanced implantable infusion pumps were tested in 
clinical trial, such as Infusaid pump, the MiniMed PIMS system and the Medtronic 
SynchorMed system (Rautio and Chikhale. 2004). These systems are able to deliver 
drug at a constant rate over a prolonged period of time at the brain tumor site through 
the outlet catheter, and they can be refilled by subcutaneous injection.   Despite 
encouraging results, there are still a lot of flaws limiting the success of this type of drug 
delivery system, such as infection, catheter obstruction and discomfort to the patient.  
  
2.2.2.2 Local implantation of sustained controlled release polymer 
 The objective of implantable polymer for brain tumor therapy is to provide a 
continuous drug delivery to the brain tumor using a matrix that also protects the drug 
from degradation. The first generation of controlled release polymer system is based on 
non-biodegradable polymer.  Langer and Folkman first reported the sustained and 
controlled release of macromolecules from ethylene vinyl acetate copolymer (EVAc) 
(Langer and Folkman. 1976).  The encapsulated drug is released by diffusion through 
the micropore of the polymer matrix.  Although EVAcs have found applications in 
glaucoma, diabetes and asthma therapy, it is not specifically FDA approved for use in 
the brain (Lesniak and Brem 2004).  
  The major step for utilizing the controlled release polymer in brain tumor 
therapy is the development of biodegradable polymer system.  Brem and coworkers 
have studied the treatment of recurrent malignant glioma with the anticancer drug 
carmustine via a biodegradable polymer as a polyanhydride wafer (Brem & Gabikian 
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2001).  This biodegradable polymer, poly[bis(p-carboxyphenoxy)propane-sebacic acid 
](p(CCP-SA)), releases drug by both hydrophobic degradation and drug diffusion.  They 
demonstrated that this polymer system is biocompatible and sustained release of 
carmustine in a preclinical study (Brem et al. 1991). After clinical trials, FDA finally 
approved carmustine loaded p(CCP-SA) wafer (Gliadel®) for the treatment of malignant 
glioma.  Although it has been used clinically, one of the limitations of this p(CCP-SA) 
copolymer is that it is designed for delivery of  hydrophobic molecules. To overcome 
this limitation, the fatty acid dimer-sebacic acid (FAD-SA) copolymer, another 
biodegradable polymer, was developed for delivery of hydrophilic molecules (Domb et 
al 1991).  These two biodegradable polymers share the same mechanism of release and 
the possibility to vary the release kinetic by varying the ratio of the two monomers. 
Among the few biodegradable polymers, poly(latide-co-glycolide) (PLGA) has 
been extensively studied as a drug transport vehicle in controlled release delivery 
system. An advantage of PLGA is that its degradation can be regulated by varying 
molecular weight and composition of the copolymer.  In addition, it can encapsulate 
both hydrophilic and hydrophobic therapeutic agents, thus making it better than the 
previously mentioned polyanhyidide biodegradable polymers.    
The general limitation for all the above polymeric implant systems is that drug 
release cannot be controlled once the system has been implanted, thus an increased risk 
of local neurotoxicity might occur at higher polymer or therapeutic agents concentration 





Chemotherapy of brain tumor has been particularly inefficient, due to the special 
barriers in central nervous system (CNS).  The failure of potential effective 
chemotherapeutics for brain tumor treatment is usually not due to the lack of potency of 
the drug, but rather can be attributed to lack of therapeutic strategies capable of 
overcoming CNS barriers for effective delivery of drug to the brain tumor. This chapter 
briefly summarizes invasive and non-invasive strategies to overcome the barriers.   
Particularly, we have focused more on applying the local implant strategy to enhance the 
effectiveness of drug delivery in brain tumor therapy.   Most of the implantable polymer 
systems are capable of sustained release anti-cancer drug both in vivo and in vitro, 
however, the therapeutic agents might or might not cover the tumor resection area due to 
its geometry.  Thus, developing a system that can combine both spatial and temporal 
control will benefit brain tumor therapy.  
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Conformally Coated Particle-Doxorubicin Therapy for Brain Tumor 
 
3.1 INTRODUCTION  
Chemotherapy of brain tumor has been particularly inefficient, due to the 
barriers in central nerve system (CNS), especially blood brain barrier (BBB).  The 
failure of potential effective chemotherapeutics for brain tumor treatment is usually not 
due to the lack of potency of the drug, but rather can be attributed to lack of therapeutic 
strategies capable of overcoming BBB for effective delivery of drug to the brain tumor.   
Local delivery of chemotherapeutic agents has the advantage of bypassing the BBB, 
thereby delivering a higher drug concentration at the site of interest while minimizing 
the systemic side effects.    Particularly, we have focused more on applying the local 
implant strategy to enhance the effectiveness of drug delivery in brain tumor therapy.   
Most of the implantable polymer systems are capable of sustained release anti-cancer 
drug both in vivo and in vitro, however, the therapeutic agents might or might not cover 
the tumor resection area due to its geometry.  Thus, developing a system that can 
combine both spatial and temporal control will benefit brain tumor therapy.  
  In the present study, we are pursuing the design and development of conformal 
coating technology so that the entire resected area is covered conformally with a 
hydrogel-particle composite that locally delivers doxorubicin (DOX). DOX, a 
topoisomerase II inhibitor, stabilizes the topoisomerase II complex after it has broken 
the DNA chain for replication, preventing the DNA double helix from being resealed 
and thereby stopping the process of replication (Momparler et al. 1976).  It is currently 
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used in the treatment of leukemias, Hodgkin's lymphoma, as well as cancers of the 
bladder, breast, stomach, lung, ovaries, and others (Lesniak et al. 2005),however it is 
currently not used clinically for brain tumor treatment because when delivered 
systemically it does not cross the BBB.  Our hydrogel-particle system will overcome 
this shortcoming of DOX.   
For sustained delivery, biodegradable polymeric particles made from 
poly(lactide-co-glycolide) were used for the slow release of DOX. For local delivery, 
hydrogel was used as a scaffold for the particles and allowed DOX to diffuse to the 
brain tumor cells (See Figure 3.1.A). The thermoreversible property of this hydrogel 
allows it to be liquid at 380C, and gels at physiological temperature, thus making it 
possible for conformal coating of the soft tissue surfaces, and providing an effective 
treatment of the entire surface exposed after resection.  In present study, we would 
develop the DOX encapsulated hydrogel-particle delivery system and characterize its in 
vitro performance. Followed by Evaluation of the performance of the DOX encapsulated 




A 9L glioma cell line was received as a generous donation from the 
Neurosurgery Tissue Bank at UCSF.  Rat astrocyte was kindly provided by Dr. Kacy 
Cullen of Neurolab at Georgia Tech. Minimal essential medium containing Earle’s 
balanced salt solution (MEM/EBSS) and fetal bovine serum (FBS) were purchased from 
Hyclone (Logan, UT). Gentamicin (50 mg/ml), and Leibovitz’s L-15 medium were 
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                                      A. Schematic of DOX/PLGA gel system 
 
B. Images of implantation of DOX/PLGA particle gel system. 
 
Figure 3.1. Local sustained release system. A. Schematic of DOX/PLGA gel system.  
he 
l 
DOX released from DOX/PLGA particle into the hydrogel, then diffused into the 
surrounding tissue.  B. Image of implantation of DOX/PLGA particle gel system. T
surgical incision used for inoculating the tumor was reopened 5 days later.  The dental 
acrylate resin and hydrogel were carefully removed. Prior to polymer-gel implantation 
the dura was gently pierced and retracted with fine micro-forceps.  The animals were 
then intracranially implanted with either a DOX encapsulated gel system (25 µL), or 
with DOX/PLGA particle encapsulated in gel system (25 µL).  After fixing with denta
acrylate resin, the skin was sutured closed.
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obtained from Gibco (Carisbad,CA). DMEM/F12 50/50 mixture 1X with L-Glutamine 
and 15 mM HEPES, 0.05 % Trypsin-EDTA (0.05% trypsin, 0.53mM EDTA) and 0.25% 
Trypsin (0.25% trypsin, 2.21 mM EDTA), Penicillin-Streptomycin Solution (Pen-Strep) 
were purchased from Mediatech (Herndon, VA). Isoflorane and Doxorubicin (DOX) 
were obtained from Baxter Healthcare (Deerfield, IL). Ketamine (100 mg/ml) was 
purchased from Fort Dodge Laboratories (Madison, NJ).  Marcaine (0.5%) was obtained 
from Abbott Laboratories (Abbott Park, IL).  Flunixin meglumine was purchased from 
Phoenix Scientific (San Marcos,CA).  Xylazine (100 mg/ml) was purchase from Bulter 
Company (Dublin, OH). Acetylpromise (10mg/ml) was obtained from Boehringer 
Inglheim (Ingelheim, Germany). Poly vinyl alcohol (PVA), 87-89 hydrolized, Mw 
31000~50000) was purchased from Aldrich. Dichloromethane (DCM) reagent ACS 
99.5% was purchased from ACROS (ACROS, New Jersy).  Poly (dl-
lactide/glycolide)75:25 was purchased from Polyscience Inc(Warrington, PA). SeaKem 
GTG Agarose was purchased from Cambrex(Cambrex, Rockland, ME). 
 
3.2.2 Cell Cultures 
A 9L glioma cell line was maintained in MEM/EBSS medium supplemented 
with 10% FBS and 0.05 mg/ml gentamicin.  9L glioma cells were passaged by 
trypsinization (0.05% Trypsin/EDTA) and washed with growth medium.  Prior to 
implantation, cells were resuspended in serum-free Leibovitz’s L-15 medium to a 
concentration of 2x108 cells/mL. 
Rat astrocytes were maintained in DMEM/F12 medium supplemented with 10% 
FBS and 1% Pen-Strep.  Astrocytes were passaged by trypsinization (0.25% 
Trypsin/EDTA) and washed with growth medium. 
 
3.2.3 In vitro cytotoxicity experiment 
To determine effect of free DOX concentration and incubation time on cells, 
cytotoxicity studies were conducted by seeding 9L glioma cells and astrocytes, 
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respectively, at a density of 3000 cells per well on a 48-well plate twenty-four hours 
prior to incubation with drug. Cells were incubated with different concentrations (from 
5-1000ng/mL) of free DOX for different incubation times (2, 24, 48, 72 hours) at 37oC.  
Cells were then washed three times with fresh growth medium and re-incubated for 48 
hours.  The numbers of viable cells were determined with a water soluble formazan-
based assay (CCK-8, Dojindo, Kumamoto, Japan) in a SynergyTM HT microplate reader 
(Bio-Tek, Winooski, VT).   
 
3.2.4 Preparation of PLGA particles 
Saline and DOX loaded particles were prepared through a modified double 
emulsion method (Li et al. 2001).  Briefly, DOX was reconstituted with 0.9% Saline to 
10 mg/mL DOX solution, and 2% PLGA copolymer (75:25) was dissolved in 5 mL 
DCM.  250 µL of DOX solution was then added into 5mL PLGA solution.  The mixture 
was then emulsified three times by homogenization at 5000 rpm (13 seconds/run).  The 
resulting emulsion was then added into 50 mL of 0.4% PVA solution and homogenized 
three times at 8000 rpm (18 seconds/run).  The resulting double emulsion was stabilized 
in 150 mL of 0.1% PVA solution.  DCM was removed by evaporation in a vacuum 
chamber for 3 hours with moderate stirring.  The resulting DOX/PLGA particles were 
centrifuged at 8500 g for 15 minutes (ThermoForma High Performance centrifuge), the 
supernatant was removed and the pelleted particles were resuspended with deionized 
water.  This process of centrifugation and resuspension were repeated twice before 
lyophilization (LABCONCO Freeze Dry System/ Freezone 4.5).  The lyophilized 
DOX/PLGA particle was stored at -20oC.  The size of the particles was measured by 
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Dynamic Light Scattering (DLS) (Brookhaven Instrument Corp).  Saline encapsulated 
PLGA particles (Saline/PLGA particles) were fabricated as an experimental control.  
The fabrication procedure for Saline/PLGA particles was the exactly same as for the 
DOX/PLGA particles, except that saline was encapsulated instead of DOX.  
Encapsulation efficiency and loading was determined by measuring the amount of DOX 
in the supernatants generateed during the recovery steps of particle preparation.  The 
DOX concentration was determined by measurement of the UV absorbance at 480 nm. 
(Bio-Tek SynergyTM HT microplate reader, Winooski, VT). 
 
3.2.5 Preparation of hydrogel 
DOX loaded 1% hydrogel was prepared by dissolving 100 mg SeaKem powder 
with 10 mL of various concentrations (0.015, 0.03, 0.1, 0.5 and 2.0 mg DOX/mL) of 
DOX solution. Saline loaded 1% SeaKem gel was also prepared as an experiment 
control.   DOX/PLGA particle gel system was fabricated by encapsulating different 
amount of DOX/PLGA particles in 1% SeaKem gel.  Saline-PLGA particle gel system 
was used as an experiment control. 
3.2.6 In vitro release experiment  
200 ul of DOX loaded gel or DOX/PLGA particle gel was added to a 2 ml 
microcentrifuge tube.  After gelling, 1000 µL of saline was added and the tube was 
shaken at 60 rpm (IKA-VIBRAX-VXR electronic), 37oC.  At different time intervals, 
800 µl of the supernatant was pipetted out, and the same volume of fresh saline was 
added to the tube. The concentration of DOX released in the supernatant was measured 
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(λex=485 nm,λem=590nm) by the fluorescence spectrometer(Bio-Tek SynergyTM HT 
microplate reader, Winooski, VT).    
 
3.2.7 Bioactivity assay 
Bioactivity of the released DOX was examined by the viability of 9L glioma 
cells and rat astrocytes.  9L glioma cells and rat astrocytes were seeded at a density of 
104 cells per well on a 24-well plate twenty-four hours prior to incubation with delivery 
system. Cells were incubated with the Saline-PLGA particles, DOX/PLGA paticles, 1% 
SeaKem gel, Saline-PLGA particle in gel, and DOX/PLGA particle in gel for 24 hours 
at 37oC.  Cells were then washed three times with fresh growth medium and re-
incubated for 48 hours.  The numbers of viable cells were determined with a water 
soluble formazan-based assay (CCK-8, Dojindo, Kumamoto, Japan) in a SynergyTM HT 
microplate reader (Bio-Tek, Winooski, VT).    
 
 
3.2.8 Tumor Inoculation   
A rat glioma model was established by surgically implanting 2x106 9L glioma 
cells into the frontal lobe of 11-12 week old male Fisher 344 rats.  All procedures were 
conducted under a protocol approved by the Institutional Animal Care and Use 
Committee (IACUC) at Georgia Institute of Technology.   Adult male Fischer 344 rats 
were anesthetized with a mixture of 5% isoflurane and 1L/min O2 prior to surgery.  Each 
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animal was positioned into a stereotactic frame where anesthesia was maintained at 2-
3% isoflurane during surgery (with 0.3 L/min O2).  The surgical site was shaven and 
then cleaned with isopropyl alcohol and chlorohexaderm.  An ophthalmic ointment was 
applied on the eyes to prevent corneal abrasion during and after the surgery.  A midline 
incision was made in the scalp to expose the skull.  A dental drill was used to create a 
3.2 mm hole at a position 3mm lateral and 1mm anterior to the bregma, with a custom 
trephine (24 tooth X 3mm O.D.).  The bone plug was carefully removed.  A 22 gauge 
needle was inserted into the frontal lobe at a depth of 3mm to inject 10μl of the glioma 
cell suspension (2x106 cells).  The cells were slowly injected over a period of 
approximately 30 seconds.  Following injection of the cell suspension, the needle was 
slowly retracted over a period of approximately one minute.  The tumor injection site 
was first covered with 1% SeaKem gel followed by dental acrylate resin, after which the 
wound was closed with suture.  Animals then received 5 mL of Lactated Ringer’s 
solution through intraperitoneal (IP) injection.   Flunixin meglumine (2.5mg/kg) was 
administered through an intramuscular (IM) injection to alleviate pain as needed. 
 
 
3.2.9 Survival Studies 
The surgical incision used for tumor inoculation was reopened 5 days later.  The 
dental acrylate resin and hydrogel were carefully removed. Prior to polymer-gel 
implantation, the dura was gently pierced and retracted with fine micro-forceps.  The 
animals were then intracranially implanted with either a DOX encapsulated gel system 
(25 µL), or with DOX/PLGA particle encapsulated in gel system (25 µL) ( See Figure 
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3.1.B).  After fixing with dental acrylate resin, the skin was suture closed. Animals 
received 5 mL of Lactated Ringer’s solution through intraperitoneal (IP) injection.   
Flunixin meglumine (2.5mg/kg) was administered through an intramuscular (IM) 
injection to alleviate pain as needed. Tumor growth was allowed to progress until the 
animal showed signs of morbidity, at which point interventional euthanasia was 
administered. Time of death was determined to be the following date. The survival 
curve was statistically analyzed with Kaplan-Meier method.  
 
3.2.10 Histological examination. 
Nine Fisher 344 rats (control (n=3), DOX/PLGA gel (n=3), PBS-PLGA gel 
(n=3)) were used for histopathological examination.  Animals were perfused at Day 9 (4 
days after treatment). The brain was retrieved, and the tissue was fixed with 4% 
paraformaldehyde, blocked in OCT, coronally sectioned into 12µm samples, and stained 





3.3.1 In vitro cytotoxicity of DOX 
The cytotoxicity of DOX on 9L glioma cells as measured by viability is shown 
for each DOX concentration and incubation time in Figure 3.2. The abscissa is the 
concentration of DOX while the ordinate is the viability relative to an untreated control 
(untreated control= 100%).  As shown in Figure 3.2, at 2 hour incubation period, only 
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higher concentrations of DOX (> 200 ng/ml) had significant cytotoxic effects on 9L 
glioma cells.  However, when DOX incubation time is longer than 24 hour, we observed 
the relative viability drop into 70% at 20 ng/mL DOX and observed even lower viability 
(<25%) as the DOX concentration increased. In general, the cytotoxicity is proportional 
to DOX concentration and incubation time for 9L glioma cells. 
Comparison of the cytotoxic effect of various amount of DOX on 9L and rat 
astrocyte at different incubation time is shown in Figure 3.3. Rat astrocyte was used in 
this study as a control to represent normal healthy brain tissue.  In general, the 
cytotoxicity of DOX is proportional to DOX concentration and incubation time for both 
9L glioma cells and rat astrocytes.   However, we didn’t observed a significant decrease 
in viability of rat astrocyte when compare to 9L glioma cells. 
At 2 hour incubation period, only higher concentrations of DOX (> 100 ng/ml) 
had significant cytotoxic effects on rat astrocyte as shown in Figure 3.3.(a).  However, 
when incubation time is longer than 72 hour, we began to observe a decrease in relative 
viability even when DOX concentration was as low as 20 ng/mL (Figure 3.3.(d)). 
The relative viability of 9L glioma and rat astrocytes became significantly 





























Figure 3.2. Cytotoxic effects of various amounts of DOX on 9L glioma at 
different incubation times.  Cytotoxicity studies were conducted by seeding 9L 
glioma cells at a density of 3000 cells per well on a 48-well plate twenty-four 
hours prior to incubation with drug. Cells were incubated with the different 
concentrations (from 5-1000ng/mL) of free DOX for different incubation times (2, 
24, 48, 72 hours) at 37oC.  Cells were then washed three times with fresh growth 
medium and re-incubated for 48 hours. Relative viability is obtained by comparing 

































































































Figure 3.3. Comparison of cytotoxic effect of various amounts of DOX on 9L 
glioma  and rat astrocyte at (a) 2 hour, (b) 24 hour, (c) 48 hour and (d)72 hour 
incubation.  Cytotoxicity studies were conducted by seeding 9L glioma cells and rat 
astrocytes at a density of 3000 cells per well on a 48-well plate twenty-four hours 
prior to incubation with drug. Cells were incubated with the different concentrations 
(from 5-1000ng/mL) of free DOX at 37oC.  Cells were then washed three times with 
fresh growth medium and re-incubated for 48 hours. Relative viability is obtained by 
comparing each group with non treated group. 
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higher than 50 ng/mL.  For example, when incubating 9L glioma with 50 ng/mL DOX 
for 24 hour period, the relative viability of 9L glioma dropped to 25%, while the rat 
astrocytes still showed 80% viability at the same condition.  The difference of viability 
between 9L glioma and rat astrocytes became bigger as the DOX concentration become 
higher. 
 
3.3.2 Particle characterization and loading efficiency 
Biodegradable PLGA based particles were prepared by double emulsion method.  
The yield of the particle after lyophilization is 63.7%. The DOX loading efficiency was 
10.1% (w/w%, DOX loaded /initial DOX amount), and the drug content of the particle 
was 3.85µg DOX per mg DOX/PLGA particle. The particles have a size range of 200-
1000 nm and the mean size of the particle is 631.1± 363.4 nm. 
 
3.3.3. In vitro release of DOX 
3.3.3.1. In vitro release of DOX from 1% SeaKem gel. 
The release profile of DOX from 1% SeaKem gel is shown in Figure 3.4.  We 
observed a burst release with in first 6 hours.  Approximately 80% of free DOX released 
in the first 12 hour for all concentrations, and no further release was observed after 24 
hours. The results showed that initial loading concentration of DOX did not affect the 




Figure 3.4. Cumulative release of DOX from 1.0 % SeaKem gels at different 
DOX concentrations. (2.0, 0.5, 0.1, 0.03 and 0.015 mg/mL) at 37oC. 200 ul of 
DOX loaded gel was added to a 2 ml microcentrifuge tube.  After gelling, 1000 µL 
of saline was added to the centrifuge tube and shake at 60 rpm, 37oC.  At different 
time intervals, 800 µl of the supernatant was pipetted out, and immediately after 
that the same volume of saline was added. The concentration of DOX released in 
the supernatant was measured (λex=485 nm,λem=590nm) by the fluorescence 
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3.3.2 In vitro release of DOX from DOX/PLGA particle gel system 
The cumulative release profile of DOX from DOX/PLGA particle gel system is 
shown in Figure 3.4 (A).  Approximately 6 μg of DOX was released from DOX/PLGA 
particle gel (40 mg DOX/PLGA particle in 200 μL of 1% SeaKem) in 15 days period.  
3.5 μg of DOX was released within the first day.  After initial burst release in Day 1, 
DOX was continuously released at a rate of 0.5~0.75 μg per day between Day 2 and 
Day 5.  Very small amount of DOX was released after Day 6.  
To study the differences of DOX release mechanism between DOX gel and 
DOX/PLGA particle gel system, we conducted a similar release experiment.  We 
prepared a 200 μL of DOX gel contained 7.5 μg DOX.  We assumed a total release 
amount of 6 μg (80% of 7.5 μg ) of DOX would be released from previous DOX gel 
release experiment as described in section 3.3.1.  As shown in Figure 3.5.(B),  the 
DOX/PLGA gel system has lower burst effect and  has more constant release when 
compare to DOX gel. 
 
3.3.4 Bioactivity of DOX/PLGA particle gel system 
The bioactivity of the released DOX was examined by the viability of 9L glioma 
cells and rat astrocytes.  As shown in Figure 3.6.  DOX/PLGA gel system reduced 9L 
glioma viability to 38% after 24 hour incubation, while the rat astrocytes still showed 
80% viability under the same condition.  Saline/PLGA gel was used as our negative 
control in this bioactivity experiment.  We observed that there is no reduction of 
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Figure 3.5. In vitro release of DOX.  A. In vitro release assay of DOX over the first 15 
day from DOX/PLGA gel (contain 40 mg of DOX/PLGA particle). The graph shows 
that an initial burst released in the first 4 days.  B. In vitro release assay of DOX over 
the first 48 hours from DOX/PLGA gel (contains 40 mg of DOX/PLGA particle) and 
DOX gel (contains 7.5 μg DOX). The graph shows DOX-gel released 6.5 μg DOX in 


























Figure 3.6. Bioactivity assay for DOX particle gel system. The bioactivity of the 
released DOX was examined by the viability of 9L glioma cells and rat astrocytes.  9L 
glioma cells and rat astrocytes were seeded at a density of 104 cells per well on a 24-
well plate twenty-four hours prior to incubation with delivery system. Cells were 
incubated with the 300 ug of Saline/PLGA particle in gel and 300 ug of DOX/PLGA 
particle in gel for 24 hours at 37oC.  Cells were then washed three times with fresh 
growth medium and re-incubated for 48 hours.  The numbers of viable cells were 
determined with a water soluble formazan-based assay (CCK-8, Dojindo, Kumamoto, 
Japan) in a SynergyTM HT microplate reader (Bio-Tek, Winooski, VT).   The data shows 




3.3.5 Survival Studies 
The therapeutic effect of DOX gel and DOX/PLGA particle gel treatment was 
determined by comparing the respective survival times in response to treatment type 
(Figure 3.7.)  Treatments were intracranial implantation of 25 uL of DOX gel or 
DOX/PLGA gel at a DOX dosage of 100 ug/kg five days after tumor inoculation. 
Equivalent volume of PLGA particle gel was implanted serving as negative control. As 
shown in Figure 3.7., a statistically significant increase in survival time was observed 
for both DOX gel (p<0.05) and DOX/PLGA particle gel treatments (p<0.01), in 
comparison to non-treated animals.  However, no significant difference was observed in 
survival between DOX gel and DOX/PLGA particle gel treatments (p=0.69).  
 
3.3.6 Histology Evaluation 
As shown in Figure 3.8 (A) the tumor cells were confined in the injection area in 
the untreated animal.    For DOX/PLGA particle gel (Figure 3.8 (B)) and DOX gel 
(Figure 3.8 (C)) treated group, the tumor cells were less than the untreated group.  For 
Saline/PLGA particle gel treated group, the tumor cells migrate all the way from 
injection site to the surface of PLGA gel implantation site.  We also observed damage 
near the surface of implanting site in these three treated groups (Figure 3.8. (B), (C), and 
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Figure 3.7. Survival study. The therapeutic effect of DOX gel and DOX/PLGA particle 
gel treatment was determined by comparing the respective survival times in response to 
treatment type. Treatments were intracranially implanted 25 uL of DOX gel or 
DOX/PLGA gel at a DOX dosage of 100 ug/kg five days after tumor inoculation. 
Equivalent volume of PLGA particle gel was implanted as a negative control group. The 
data show a statistically significant increase in survival times for both DOX gel (p<0.05) 
and DOX/PLGA particle gel (p< 0.01) treatments when compared to non-treated or 
saline/PLGA treated animals. There is no significant difference between DOX/PLGA 
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Figure 3.8. Haematoxylin and eosin stain (H&E)-stained coronal sections (12μm) of rat 
brains 9 days after tumor inoculation. (A) Untreated, (B)Treated with DOX/PLGA 
particle gel, (C) Treated with DOX gel, and (D) Treated with saline/PLGA particle gel 
at Day 5 after tumor inoculation. The pink area represents normal brain tissue and the 






Implantable biodegradable polymer system has been used for brain tumor 
therapy to provide a continuous drug delivery to the brain tumor and protect the drug 
from degradation.  The present study was initiated in an effort to incorporate drug 
loaded biodegradable particles into an agarose gel, which can provide a continuous 
release of therapeutic agent locally to the tumor site. This is of particular interest and 
importance because it incorporates the distinct benefits of these two families of 
materials into a single delivery system.  The only limitation in using this delivery system 
is that the therapeutic drug must be hydrophilic so that it can be released from the PLGA 
particles into the hydrogel and subsequently diffuses to the surrounding tissue.   
DOX, a hydrophilic chemotherapeutic agent, stabilizes the topoisomerase II 
complex after it has broken the DNA chain for replication, preventing the DNA double 
helix from being resealed and thereby stopping the process of replication.  Tumor cells 
replicate faster than normal cells, making them more susceptible to the presence of 
DOX.  DOX is used to treat leukemia, Hodgkin's lymphoma, as well as cancers of the 
bladder, breast, stomach, lung, ovaries, and others.  However, it is not currently used for 
brain tumor treatment since it cannot cross the blood brain barrier due to its 
hydrophilicity.  
Initially, in vitro cytotoxicity experiments were performed to test how tumor 
cells and normal cell respond to the DOX. The cytotoxic effect of DOX is proportional 
to DOX concentration and incubation time for both 9L glioma cells and rat astrocytes 
(representing normal brain tissue).   However, the results also suggest that DOX has a 
higher cytotoxic effect on 9L glioma cells.  Since DOX interferes with the process of 
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cell division and protein synthesis, when incubated with the same amount of DOX, the 
growth of fast dividing cells (9L glioma) would be easily suppressed than that of normal 
cells.  This assumption was supported by the experimental  comparison of cytotoxic 
effect of DOX on 9L cells and rat astrocytes (Figure 3.3).  
The cytotoxicity results also showed that when the cell incubation time with 
DOX was increased, the growth of 9L glioma was suppressed while the viability of 
normal cells was preserved, especially at certain DOX concentrations (50 ng/mL and 
100 ng/mL).  This suggests that a system with sustained release of DOX would benefit 
the glioma therapy with minimal toxic effect on healthy cells. 
The use of biodegradable microspheres for the delivery of anticancer agents has 
generated considerable interest.  Among the few biodegradable polymers, PLGA has 
been extensively studied as a drug carrier in control release delivery system. There are 
several advantages to using PLGA for drug delivery. One of them is that PLGA 
degradation can be regulated by varying its molecular weight and the composition of the 
copolymer (Anderson and Shive 1997).  Secondly, both hydrophobic and hydrophilic 
drugs can be encapsulated into the polymer spheres through different emulsion methods 
(Barichello et al. 1999). In addition, it degrades into biocompatible byproducts which 
can be eliminated by the normal metabolic pathways (Bazile 1992).  All these 
advantages make PLGA the ideal drug carrier for our system. 
As we mentioned before, most of the implantable polymer systems are capable 
of sustained release of anti-cancer drug, however, the therapeutic agents might not cover 
the tumor resection area due to its geometry.  To overcome this drawback, we utilize 
hydrogel as a scaffold for the particles which allows DOX to diffuse to the brain tumor 
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cells.  The use of agarose gel in the pharmaceutical and biomedical field is very 
attractive since it is nontoxic, inexpensive materials and has a very high potential for use 
with a variety of medicinal agents.  Our special interest in using SeaKem agarose gel as 
our gel system is that it gels at 37 degree without using any additional crosslinker.  Such 
thermoreversible property allows it to be liquid at 380C, and gels at physiological 
temperature, thus making conformal coating of the soft tissue surfaces possible, and 
providing an effective treatment of the entire surface exposed after resection. 
As we described in previous section, the in vitro release assay demonstrated that 
DOX was released from DOX/PLGA particle gel system for at least 15 days. When 
compared to DOX gel system, the DOX released from DOX/PLGA gel system showed 
more controlled release property and reduced the initial burst effect to 50% in the first 
24 hour. Although there is only small amount (0.1 ug) of DOX released from our system 
from day 8 to day 15, such amount of DOX should still be high enough to exert 
therapeutic effect.   The bioactivity assay also demonstrated that our DOX/PLGA 
particle gel system can preserve the potency of DOX after encapsulating in PLGA and 
agarose gel system.  Based on the results from the in vitro study, we believe that the 
same system will demonstrate similar therapeutic effect in vivo. 
Our in vivo efficacy study indicated that there was significant difference 
between animals treated with DOX/PLGA particle gel or DOX gel, and animals treated 
with Saline/PLGA particle gel or untreated animals. In particular, treatment of 
DOX/PLGA particle gel extended the medium survival time of 9L glioma bearing rats 
from 21 days to 29 days.  It is worth mentioning that no significant difference was 
observed between DOX/PLGA particle gel and DOX gel treated animals.  The results 
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were further supported by subsequent histology examination.  Both DOX/PLGA particle 
gel and DOX gel treated animals had less severe tumor than Saline/PLGA particle gel 
treated and untreated animals.  The lack of difference between DOX gel treatment and 
DOX/PLGA particle gel treatment is not yet accounted. A possible explaination could 
be that the burst release of DOX from DOX gel suppressed the growth of glioma cells in 
early-on, but the tumor growths back after the depletion of DOX.  On the other hand, the 
sustained release of DOX from DOX/PLGA gel did not suppress as many tumor cells as 
DOX gel at the early time point. However, the sustained release of DOX from 
DOX/PLGA gel eventually suppressed the growth of glioma and had similar effect as 
DOX gel treated group. 
The saline/PLGA treated animals had even shorter survival than untreated 
animals. It might be due to the hemorrhage caused by the removal of dura prior to 
implantation of the delivery device.  Histology results showed that tumor cells have 
migrated to the surface of the brain, leading to spread proliferation and consequently 
caused the early death of the animal.  We believe the same migration also occurred in 
DOX/PLGA gel treated and DOX gel treated groups, however, the released DOX from 
these two devices suppressed the migration eventually. 
 
3.5 CONCLUSION 
The present study was initiated in an effort to incorporated PLGA/DOX particle 
into a SeaKem agarose gel, which can provide a continuous release of DOX locally to 
the tumor site.  This conformally coated DOX/PLGA gel system can deliver a 
therapeutic dosage of DOX in the tumor site while minimize systemic side-effect.  The 
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results from this study demonstrated that the DOX/PLGA particle gel system can 
maintain the bioactivity of DOX and sustained release of DOX for at least 15 day in 
vitro.  We have significantly prolonged the survival time of 9L glioma bearing rat with 
this local and sustained DOX delivery system.  
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CONCLUSION & FUTURE PERSPECTIVES 
 
Malignant brain tumor is one of the most lethal forms of cancers. Treatment of 
malignant brain tumors remains a major challenge despite recent advances in surgery 
and other adjuvant therapy.  Chemotherapy of brain tumor has been particularly 
inefficient, due to the special barriers in CNS.  In this thesis, we are pursuing the design 
and development of conformal coating technology to enhance the effectiveness of DOX 
delivery in brain tumor therapy.    DOX is currently used in the treatment of leukemias, 
Hodgkin's lymphoma, as well as cancers of the bladder, breast, stomach, lung, ovaries, 
and others.  However, it is currently not used clinically for brain tumor treatment 
because when delivered systemically it does not cross the BBB and causes severe 
toxicity in the body. These limitations further suggested that DOX might be best used 
when delivered locally as an adjunct to surgery resection. 
The in vitro results from this study demonstrated that the DOX/PLGA particle 
gel system can maintain the bioactivity and sustained release of DOX for at least 15 
days.  For in vivo application, we have significantly prolonged the survival time of 9L 
glioma bearing rat with this local and sustained DOX delivery system.  While these 
results are rather promising, there is still a long way to reach our ultimate goal, to 
eradicate the remaining tumors after resection.  Thus, we will discuss future prospects 




4.1 OPTIMIZATION OF IN VIVO DOSAGE 
In the in vitro cytotoxicity experiment in Chapter 3, We observed that 
cytotoxicity of DOX on 9L and rat astrocyte is proportional to the DOX concentration 
and incubation time.  We observed that at certain concentration, DOX has more effect 
on 9L glioma, while the rat astrocytes were still viable under the same condition. 
However, only one concentration of DOX was delivered to the brain tumor site in our in 
vivo efficacy experiment.  Therefore, delivering different dosages of DOX to determine 
the optimal dosage in vivo is needed for future work. 
 
4.2 OPTIMIZATION OF DELIVERY VEHICLE 
PLGA particle gel composite was used to deliver DOX in our in vivo study. We 
also demonstrated that the PLGA particle gel composite could release DOX for at least 
15 days.  However, most of the DOX was released in the first week.  It will be benefitial 
to tumor therapy, if we could increase the duration of DOX release.  The release of 
DOX from PLGA particle is mainly controlled by the degradation rate of PLGA.  The 
advantage of using PLGA is that we could manipulate degradation rate of PLGA by 
using different ratios of the two monomers.  
The other optimization of delivery vehicle is to enhance the DOX encapsulation 
efficiency by fabricating the particle using spray drying technology instead of double 
emulsion method.  The problem of using double emulsion technique for DOX 
encapsulation is that DOX is easily lost in washing step.  Unlike emulsion methods, 
spray drying technique does not involve the use of water.  Thus, this technique is 
suitable for fabrication of DOX/PLGA particle.  Lin et al. showed that using spray 
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drying technique, they are able to increase the DOX encapsulation efficiency to 73.8% 
(Lin et al. 2007). 
 
4.3 USING BIODEGRADABLE HYDROGEL AS DELIVERY SCAFFOLD 
 Although we have proved the advantages of using agarose gel as delivery 
scaffold, there is one major limitation of this non-biodegradable hydrogel.  Like all other 
non-biodegradable implant, once the drug diffuses and is completely released, the 
agarose gel remains in place permanently as a foreign body.   One possible solution is to 
use biodegradable hydrogel.  Konishi et al. have studied the release of adriamycin 
(DOX) and cisplatin from biodegradable gelatin hydrogel (Konishi et al. 2005).  Thus, 
applying biodegradable hydrogel in our delivery system might benefit future in vivo 
work. 
 
4.4 MULTI-FACTORIAL APPROACH 
The other advantage of this particle gel composite system is that we can 
incorporate different anticancer drugs within one single device.  As mentioned before, 
only hydrophilic agents are suitable for our delivery system.  There are several 
hydrophilic anticancer drugs, such as cisplatin and 5-Fluorouracil (5-FU), which have 
been used to treat brain tumor in vitro and in vivo. These drugs have different anticancer 
properties compared to DOX.  Cisplatin acts by crosslinking DNA in several different 
ways, making it impossible for rapidly dividing cells to duplicate their DNA for mitosis. 
Promising results have been shown in studies treating 9L glioma with cisplatin (Lillehei 
et al. 1996).  
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5-FU, a pyrimidine analogue, is transformed inside the cell into different cytotoxic 
metabolites which are then incorporated into DNA and RNA, finally inducing cell cycle 
arrest and apoptosis by inhibiting the cell's ability to synthesize DNA. Menei et al. has 
reported that 5-FU was delivered locally by PLGA and achieved a significant 
concentration in cerebrospinal fluid (Menei 1999). 
A multi-factorial approach, rather than a unilateral one, can minimize the 
expression of drug-resistance in tumor cells.  Since these hyrophilic anticancer drugs 
have different mechanisms of actions on brain tumor, we propose that we will prolong 
the medium survival by the synergetic effect of these drugs. 
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